Exclusive: Successful Biotech CEO Talks Scaling from Series A to $157M Series B
businessofsandiego.substack.com
Engrail Therapeutics’s Vikram Sudarsan details its oversubscribed Series B raise and why life science investors are betting big on the future of neuroscience.
Exclusive: Successful Biotech CEO Talks Scaling from Series A to $157M Series B
Exclusive: Successful Biotech CEO Talks…
Exclusive: Successful Biotech CEO Talks Scaling from Series A to $157M Series B
Engrail Therapeutics’s Vikram Sudarsan details its oversubscribed Series B raise and why life science investors are betting big on the future of neuroscience.